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Abstract
The role of haptoglobin in osteoclastogenesis
Won Jong Jin
Department of Cell and Developmental Biology
The Graduate School
Seoul National University
(Directed by Prof. Zang Hee Lee, D.D.S., Ph.D)
Haptoglobin (Hp), a member of the acute phase proteins, is known to be a 
major hemoglobin (Hb)-binding protein that plays a protective role against Hb-
induced cytotoxicity in various organs. Hp is primarily expressed in hepatocytes, 
and recent studies have shown its expression in other cells, such as 
keratinocytes, leucocytes, fibrocytes and adipocytes. However, the involvement 
of Hp in bone-related cells has not been fully understood. In this study, I 
investigated the effects of Hp in osteoclastogenesis and skeletal health. 
Inflammatory cytokines, interleukin-1α (IL-1α), tumor necrosis factor α (TNF-α) 
and lipopolysaccharide (LPS) induced Hp secretion in the bone-forming cells, 
osteoblasts. Histo-morphometric analyses indicated that the deletion of Hp gene 
showed significant bone loss with increasing osteoclast formation. 
Administration of Hp in Hp knockout (Hp-/-) mice stimulated a higher bone 
volume increment than that in PBS-injected mice. Consistent with the in vivo
results, IL-1α-induced osteoclast formation by co-culture of Hp null calvarial 
osteoblast and wild-type (WT) bone marrow-derived macrophages (BMMs) 
showed increase higher osteoclastogenesis than that observed in WT osteoblast 
in vitro. Stimulation of Hp inhibited osteoclastogenesis by suppression of major 
transcription factors such as c-Fos and NFATc1 expression. Overexpression of 
c-Fos in osteoclast precursor cells rescued Hp-mediated suppression of 
osteoclastogenesis with promotion of its down-stream master transcription 
factor, NFATc1. I found that Hp-induced suppression of c-Fos expression was 
mediated by an increase in interferon beta (IFNβ) levels, a well-known c-Fos 
inhibitor. Hp-induced inhibition of osteoclastogenesis substantially recovered 
following treatment with IFNβ-specific neutralizing antibody and IFN-type I 
receptor knockout cells. In addition, I determined that Hp-induced IFNβ
expression was activated via toll-like receptor 4 (TLR4). Flow cytometer 
analysis showed that stimulation of Hp or the well-known TLR4 ligand, LPS 
induced TLR4 internalization. Furthermore, a binding assay for TLR4 showed 
direct interaction of Hp to TLR4 when I compared to that of bovine serum 
albumin (BSA) interaction. Taken together, these results demonstrate that 
inflammation-induced secreted-Hp from osteoblast plays a protective role 
against excessive osteoclastogenesis via the TLR4-IFNβ signaling pathway.
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I. Introduction
I.1. Bone remodeling and diseases
Bone is a metabolically active organ that continuously undergoes resorption 
and renewal during lifetime. The bone homeostasis is mainly regulated by a 
delicate balance of bone cells—osteoblasts and osteoclasts (Fig. 1). This 
process, termed “remodeling” is mainly achieved by coupling of osteoblasts
and osteoclasts which facilitates various functions, including mechanical 
support, protection for tissues, calcium release, and hematopoiesis (Rodan, 
1998). Several factors such as ephrin B2/EphB4, Semaphorin 4D/PlexinB1, and 
Ephhrin A2/EphA2 interaction have been proposed as osteoblast and osteoclast 
coupling factors (Irie et al., 2009; Negishi-Koga et al., 2011; Zhao et al., 2006). 
Disparity in processing between osteoblasts and osteoclasts results in 
pathological bone diseases such as osteoporosis, Paget’s disease, and 
rheumatoid arthritis (Manolagas and Jilka, 1995). These osteoporotic diseases 
are well characterized by excessive osteoclast activation over osteoblast-
mediated bone formation, which has been shown to result in loss of bone 
quantity and quality. Thus, understanding of this coupling mechanism is 
required to take measures to ensure appropriate bone mass maintenance and 
limit its pathophysiological role in bone-related disorders. According to the 
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report of Korean Society for Bone and Mineral Research (KSBMR), 50% of 
patients with osteoporosis and femur shaft fractures are unable to recover to 
original mobility. The patient mortality has reached an intra-annual rate of 20%
(KSBMR, 2015). Therefore, the molecular basis of osteoclast activation needs 
to be investigated in order to prevent bone fragility and increase the quality of 
life.
3
Figure 1. Bone resorption by osteoclast and bone formation by osteoblast 
maintained a balance to prevent pathological bone diseases. Bone is 
continuously remodeled, with a balance maintained between osteoclasts and 
osteoblasts. Disruption of this balance provokes pathological bone diseases and 
osteopetrotic or osteoporotic disorders.
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I.2. Osteoclastogenesis and RANKL-signaling
Osteoclasts—the multinucleated bone resorptive cells—originated from 
monocyte/macrophage lineage cells in which osteoclast differentiation is 
mainly induced by cytokines, macrophage colony stimulating factor (M-CSF),
and receptor activator of NF-κB ligand (RANKL) (Kodama et al., 1991; Lacey 
et al., 1998). Indeed, the interaction between RANKL and it receptor RANK 
plays a key role in osteoclast differentiation through sequential steps of
polarization-fusion-maturation, while M-CSF is considered as an essential
factor for the survival and induction of RANK expression on osteoclast 
precursor cells (Arai et al., 1999). RANKL is a member of the tumor necrosis 
factor (TNF) receptor family that is expressed on bone marrow stromal cells 
and osteoblasts resulting from stimulation by several inflammatory cytokines, 
such as IL-1, IL-6, TNFα and lipopolysaccharide (LPS) (Collin-Osdoby et al., 
2001). Thereby, inflammatory factors contribute to osteoclastogenesis from its 
precursor cells through induction of RANKL on osteoblasts.
Signal transduction by RANKL/RANK-binding induced recruitment of TNF 
receptor-associated factor 6 (TRAF6), consistently activates various 
downstream signaling pathways, including nuclear factor-kappa B (NF-κB), 
mitogen-activated protein kinases (MAPKs), and calcium signaling pathway.
Under RANKL stimulation, TRAF6 activates a complex consisting of IκB 
5
kinase (IKK) to induce the phosphorylation and degradation of Inhibitor of 
kappa B (IκB), which releases P65/P50 heterodimers for translocation into the
nucleus. Therefore, the activation of the canonical NF-κB signaling pathway 
results in the expression of c-Fos, an early stage transcription factor, and its 
downstream target, nuclear factor of activated T-cell, cytoplasmic 1 (NFATc1), 
both of which are important transcription factors for osteoclastogenesis (Boyce 
et al., 2015). The RANK-TRAF6 binding induces the activation of 
phospholipase C gamma (PLCγ)-calcium signaling for Ca2+-dependent NFATc1 
regulation. Signaling via MAPKs-JNK, ERK and P38-is also involved in the 
activation of c-Fos and NFATc1 in osteoclastogenesis (Soysa et al., 2012) (Fig. 
2). Indeed, it has been reported that forced expression of NFATc1 promotes 
osteoclastogenesis without RANKL stimulation in precursor cells (Takayanagi 
et al., 2002a). Therefore, RANKL-induced NFATc1 is considered as the master 
transcription factor for osteoclastogenesis from bone marrow-derived 
macrophages (BMMs), the precursor cells. Consequently, the transcription 
factor NFATc1 regulates not only osteoclast-specific genes including tartrate-
resistant acid phosphatase (TRAP), cathepsin K, and osteoclast-associated 
receptor (OSCAR), but also matrix metalloproteinases (MMPs). Thus, the 
expression of NFATc1 target genes confers bone resorptive functions to
osteoclasts (Nakashima and Takayanagi, 2011).
6
Figure 2. RANKL-induced intracellular signaling network of osteoclast
differentiation. The binding of RANKL to its receptor RANK induces the 
recruitment of TRAF6, an adaptor molecule, in the cytoplasm. This interaction 
leads to the activation of various intracellular signaling cascades, such as the 
NF-κB, MAPKs, and calcium signaling cascades. RANKL-induced dissociation 
of IκB from NF-κB results in nuclear translocation of NF-κB to regulate c-Fos 
and NFATc1. RANKL-induced activation of MAPKs, such as ERK, JNK, and 
P38, activates the transcription factor c-Fos. The key transcription factor 
NFATc1, localized to the nucleus by Ca2+ signaling, is also activated by NF-κB 
and MAPKs signaling activation. These signaling complexes affect 




Haptoglobin (Hp) is an abundant plasma glycoprotein identified by 
Plononovski and Jayle (1938) (Raynes et al., 1991). Hp is mainly synthesized 
by hepatocytes in liver and is released into the blood. At sites of injury, IL-6 is 
released by leukocyte and delivered to liver via the blood stream to stimulate 
expression of Hp in hepatocytes (Heinrich et al., 1990). The fundamental role of 
Hp is to bind to hemoglobin (Hb) released as a result of erythrocyte hemolysis
and thereby to protect toxic Hb-induced oxidative stress and inflammation 
(Tseng et al., 2004). Erythrocytes can rupture during several pathological 
conditions, such as autoimmune disorders, malaria, hemoglobinopathies, and 
infections (Rother et al., 2005). Therefore, extracellular Hb, originating from 
hemolysis of RBCs, continuously undergoes autoxidation, which produces
superoxide that then dismutates into hydrogen peroxide (H2O2) (Rifkind et al., 
2014). The resulting superoxide, H2O2, and the reactive oxygen species (ROS) 
subsequently induce oxidative stress in cells. These oxidative reactions 
contribute to pathological conditions, including sickle cell disease, kidney 
dysfunction, atherosclerosis, and hemolytic anemia (Rifkind et al., 2014). 
Therefore, Hb-Hp binding has been shown to play a protective role against Hb-
induced tissue damage. It is well known that the Hb-Hp complex binds to the 
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CD163 scavenger receptor on the surfaces of macrophages and monocytes 
(Kristiansen et al., 2001). Hb-Hp-induced CD163 internalization leads to the 
enzymatic activation of heme oxygenase (HO), which degrades the hemoglobin 
subunit, heme into biliverdin, which is converted to carbon monoxide, bilirubin, 
and free iron; this restores cellular homeostasis. Hp has also been reported to be 
associated with high glucose tolerance, glucose-stimulated insulin secretion, 
and adiponectin expression (Lisi et al., 2011). This group showed that insulin-
induced phosphorylation of the AKT S473 was higher in the liver, skeletal 
muscle, and white adipose tissue of Hp-deficiency mice than in the same tissues 
in wild type mice. Bertaggia et al showed downregulation of antioxidants 
expression in the tibialis anterior muscle of Hp-deficient mice and that the 
absence of Hp affects muscle force generation and resistance to fatigue 
(Bertaggia et al., 2014). In addition, they also showed impaired antioxidant 
response and exacerbated oxidative stress in Hp-deficient mice. Collectively, 
these data indicate that Hp plays a pivotal role in various tissue metabolic 
activities and functions (Fig. 3). However, the precise molecular mechanisms of 
Hp-induced cellular signaling remains poorly understood.
In addition to liver, several recent studies demonstrated that Hp is expressed 
in other tissues, such as lung, skin, and kidney (D'Armiento et al., 1997).
Furthermore, Hp participates in adiposity, new vessels formation, fibroblast 
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migration, and graft rejection (Cid et al., 1993; de Kleijn et al., 2002; Maffei et 
al., 2016; Shen et al., 2015). Importantly, El-Ghmati et al showed that Hp binds 
to a various immune cells, including monocytes, granulocytes, and natural killer 
cells via CD11b/CD18 receptor (El Ghmati et al., 1996). Another group 
revealed that Hp binds to B lymphocytes through CD22 (Hanasaki et al., 1995). 
The binding of Hp to CD22, inhibited signaling induced by other ligands and 
consequently negatively regulated the B lymphocyte function. More 
interestingly, a recent study showed that Hp can bind to chemokine (C-C motif) 
receptor 2 (CCR2) (Maffei et al., 2009). The authors of this study observed that 
Hp stimulation (treatment at 50 or 100 μg/ml) induced monocyte migration 
through binding with CCR2 and internalized CCR2-mediated activation of its 
downstream signal transducer ERK phosphorylation. Collectively, these 
previous reports suggest that Hp has the potential to bind with several receptors 
apart from Hb, thereby carrying out numerous biological functions.
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Figure 3. Biological functions of Hp. Hemolytic conditions, such as malaria, 
bacterial infection, sickle cell anemia, and severe injury induce red blood cell 
(RBC) lysis. Released free hemoglobin (Hb) from dead RBC is rapidly captured 
by Haptoglobin (Hp), and Hb-Hp complexes bind to the receptor CD163 that 
mediates a rapid endocytosis of the complexes on monocytes and macrophages. 
Hb-Hp complexes are degraded in lysosomes and this process is followed by 
heme releasing, and heme oxygenase (HO) catalyze conversion of heme 
fraction into biliverdin, carbon monoxide, and iron. Consequently, Hp prevents 
free Hb-induced inflammation and oxidative stress, and distributes restoration 
of iron by transport it to bone marrow.
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I.4. Purpose of this study
It is well characterized that inflammation induces bone destruction by 
exerting RANKL expression in osteoblast to generate osteoclast formation. In 
line with RANKL induction, it has been reported that stimulation of 
inflammatory cytokines induced haptoglobin secretion (Heinrich et al., 1990). 
From this previous report, it is hypothesized that secreted-Hp may affect 
osteoclast differentiation. The aim of this thesis is to conduct studies on 
defining the role of Hp in osteoclast differentiation from osteoclast precursor
cells—macrophages and to identify regulation of cellular metabolism in 
osteoclastogenesis. This study will contribute to understand the fundamental 
role of Hp as a coupling factor for osteoblast and osteoclast in bone biology, 
which in turn permits pivotal role of Hp in bone homeostasis maintenance.
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II. Materials and Methods
II.1. Animal experiments
All animal experiments were performed in accordance with the Animal Care 
Committee of the Institute of Laboratory Animal Resources of Seoul National 
University (Seoul, Korea). C57BL/6.Hp-/- (Hp KO) mice were kind gifts from 
Dr. Lee Ann Garrett-sinha (Huntoon et al., 2013). 8-weeks-old male WT or Hp-
/- mice (n = 6 per group) were intraperitoneally injected with PBS or RANKL (1
mg/kg of body weight) for every day. After 4 times injection, the mice were 
euthanized and the femurs were flash-frozen in liquid nitrogen and stored at -
80 °C for RNA extraction or fixed in 4% paraformaldehyde for micro-computed 
tomography (μCT) measurement. The femurs were analyzed by high-resolution 
μCT (SMX-90CT system; Shimadzu, Kyoto, Japan). Scanning images from 
μCT were reconstructed by VG Studio MAX 1.2.1 program (Volume Graphics, 
Heidelberg, Germany). Each three-dimensional images were analyzed to 
measure bone volume, cortical bone volume, trabecular number, and trabecular 
separation by use of the TRI/3D-VIE (RATOC System Engineering, Kyoto, 
Japan).
Hp-injected animal model was performed by administration of PBS or mHp 
(100 μg/head) in 8-weeks-old male (n = 6 per group). Injection was 
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intraperitoneally administrated every other day after starting day. The mice 
were euthanized on day 14, and analyzed by μCT as described above.
II.2. Histology
The samples from animal experiments were decalcified with 12% EDTA for 
3 weeks and embedded in paraffin. After histological sagittal sections (5 μm
thickness), femurs were stained with tartrate-resistant acid phosphatase (TRAP)
solution by use of Leukocyte Acid Phosphatase Assay kit with manufacturer’s 
instructions (Sigma-Aldrich) or with hematoxylin and eosin (H&E) solution 
(Sigma-Aldrich). Appeared osteoclasts by TRAP stain were measured by use of 
OsteoMeasure XP program (version 1.01;OsteoMetrics, Decatur, GA, USA). 
II.3. Reagents and antibodies
Recombinant human M-CSF, RANKL, bone morphogenetic protein 2 (BMP-
2), mouse IL-1α, and LPS were obtained from PeproTech EC (London, UK). 
Plasma-derived human Hp and human Hb were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Mouse plasma-derived Hp was obtained from Lee 
Biosolutions (St. Louis, MO, USA). To detect target protein expression, 
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antibodies against NFATc1, c-Fos, and TLR4 were purchased from Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA, USA). Antibodies against TLR4, FLAG 
and β-actin were purchased from Sigma-Aldrich. Secondary antibodies 
conjugated with horseradish peroxidase were obtained from Sigma-Aldrich.
The specific neutralizing antibody against Toll-like receptor 4 (TLR4) was 
purchased from eBioscience (San Diego, CA, USA). The specific neutralizing 
antibody against IFN-β was purchased from PBL biomedical Laboratories 
(Piscataway, NJ, USA). The normal mouse IgG was purchased from Santa Cruz.
II.4. Cells and culture system
C57BL/6.TLR2-/-, C57BL/6.TLR4-/-, and C57BL/6.TLR7-/- mice were the 
kind gifts from professor Sungjoong Lee (Oh et al., 2011). Bone marrow cells 
were obtained by flushing bone marrow from femur and tibia of six-weeks-old 
male mice. The nonadherent bone marrow cells were further cultured with M-
CSF (60 ng/ml) for 3 days with α-MEM to generate bone marrow-derived 
macrophages (BMMs) as described previously (Kim et al., 2013). To generate 
osteoclastogenesis, BMMs (4 X 104 cells/well) were cultured in 48-well plates 
with complete medium; α-MEM containing 10% heat inactivated fetal bovine 
serum (FBS) and 50 units/ml of penicillin in the presence of M-CSF (60 ng/ml) 
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and RANKL (100 ng/ml) for 4 days. The media was exchanged every 3 days. 
Appeared osteoclasts were washed with PBS, fixed with 3.7% formalin, and 
then stained for TRAP. Calvarial osteoblasts were isolated from calvariae of 
newborn mice as described previously (Lee et al., 2009). To generate osteogenic 
differentiation, osteoblasts were cultured in 48-well tissue culture plates 
precoated with collagen at a density of 5 X 104 cells/well. After culturing for 24 
h, the cells were further cultured in osteogenic medium: α-MEM complete 
medium containing 10 mM β-glycerophosphate (Sigma Aldrich), 50μg/ml 
ascorbate-2-phosphate (Sigma Aldrich), and the 100 ng/ml of BMP-2 
(PeproTech). The medium was replaced every 3 days. After culturing, the cells 
were fixed with 10% of formalin, then incubated with 0.1% Triton X-100 for 10 
minutes. osteoblast differentiation was measured by alkaline phosphatase (ALP) 
or Alizarin Red S staining as manufacturer’s instructions (Sigma-Aldrich).
The co-culture system was examined by culturing of BMMs (1 X 105
cells/well) and osteoblast (2 X 104 cells/well) with IL-1 (20 ng/ml) in 48-well 




To analyze the secreted-Hp and secreted-IFN-β level, supernatant medium 
from cultured cell was harvested and centrifuged at 3000 rpm for 5 min to 
remove cell. Then, supernatant medium was recollected and measured by use of 
IFN-β ELISA kit (PBL) or Hp ELISA kit (Abnova, Taipei City, Taiwan) 
according to the manufacturer’s instruction.
II.6. FITC-labeling and immunostaining
Fluorescein isothiocyanate (FITC) labeling of Hp was performed by using 
FluoroTagTM FITC Conjugation kit (Sigma-Aldrich) according to 
manufacturer’s instruction. BMMs were cultured in cover glasses plate in 12-
well plate in the presence of M-CSF (60 ng/ml). After 24 h, Hp-FITC was 
added into cells, and incubated at 37°C for indicated time. The cells were 
washed with PBS for 2 times, and fixed with 3.7% formalin for 30 min. After 
blocking the cells with 1 % bovine serum albumin (BSA) in PBS for 30 min, 
antibody against TLR4 (2 μg) in 1 % BSA in PBS were added. After 1 h 
incubation on locker, the cells were washed with PBS for 3 times on the shaker. 
Then, anti-rabbit IgG antibody conjugated to Cy3 (Invitrogen) in 1 % BSA in 
PBS was added on cells and incubated for 30 min in dark room. The 
immunostained cells were observed under a confocal laser microscope 
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(Olympus FV-300, Tokyo, Japan).
II.7. Flow cytometry
BMMs (2 X 106 cells per dish) were cultured with M-CSF (60ng/ml) in 100 π
culture dish. After 24 h incubation, the cells were treated with PBS, Hp (20 
μg/ml) or LPS (1 μg/ml) for indicated time respectively. After incubation, the 
cells were detached by enzyme-free cell dissociation buffer (Millipore, Billerica, 
MA, USA). The cells were stained with anti-TLR4 antibodies, followed by 
FITC-conjugated anti-rat IgG, and analyzed by flow cytometry using a 
FACSCalibur (BD Biosciences, San Diego, CA, USA). Cells stained with 
isotype control antibodies were used as a negative control.
II.8. Cell viability assay
The cells (1 X 104) were cultured on 96-well culture plates. After 12 h 
incubation, the media was exchanged with PBS or the indicated doses of Hp. 
After indicated time of incubation, 10 μl of EZ-Cytox solution (Daeillab 
Service, Seoul, Korea) was added to each well of the plate. After incubation for 
2h, the absorbance was measured by Multiskan (Thermo Labsystems, 
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Philadelphia, PA, USA) at 450 nm.
II.9. Western blot
To detect specific protein expression, the cells were lysed on ice with a buffer 
containing 20 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, protease 
inhibitor, and phosphatase inhibitor (Sigma Aldrich). After 30 min lysis in ice, 
the cellular debris was removed by centrifugation at 13,200 rpm for 15 min. 
The supernatant was collected in tube and protein concentration was determined 
by use of DC Protein Assay Kit (Bio-Rad, Hercules, CA, USA). The protein 
samples (20-50 μg) were separated by SDS-PAGE and electrotransferred onto 
polyvinylidene difluoride membrane (GE Healthcare, Chalfont St. Giles, 
Buckinghamshire, UK). The membrane was blocked with 5% skim milk, and 
target proteins were detected by indicated primary antibodies for overnight 
attaching. Attaching of secondary antibodies conjugated with horseradish 
peroxidase were used for blotting and were visualized by chemiluminescence 
reaction using ECL reagents (GE Healthcare).
II.10. Gene transduction and retroviral infection
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Gene transduction was performed by use of Plat. E-retroviral packaging cells 
(Cell Biolabs, San Diego, CA, USA) according to the manufacturer’s 
instruction. Retroviral vectors pMX-FLAG and pMX-constitutively active 
(CA)-c-Fos-FLAG, and pMX-constitutively active (CA)-NFATc1-FLAG were
kindly provided by Dr. Nacksung Kim (Lee et al., 2009). The retroviral vectors 
were transiently transfected on Plat. E cell by using Genjet transfection reagent 
(SignaGen, Gaithersburg, MD, USA). After incubation for 48 h, supernatants 
containing retrovirus were collected. BMMs were then transduced with the 
retroviral supernatants in the presence of polybrene (6 μg/ml, Sigma-Aldrich) 
and M-CSF (60 ng/ml) for 12 h incubation. The cells were further cultured with 
puromycin (2 μg/ml) and M-CSF (60 ng/ml) for 3 days to remove uninfected 
cells. 
II.11. Conventional and real-time PCR
To measure relative mRNA expression level, total RNA was isolated by use 
of TRIzol reagent (invitrogen). 2 μg of total RNA was used for first-strand 
cDNA synthesis by using SuperScript II Preamplification System (Invitrogen). 
For PCR amplification to target mRNA expression, 20 to 30 cycles were 
performed for each gene. PCR products were separated on a 1 to 1.2 % (v/v) 
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agarose gel, stained with ethidium bromide, and detected by ultraviolet light. 
The relative mRNA expressions were evaluated by ABI Prism 7500 sequence 
detection system with SYBR Green PCR Master Mix (Applied Biosystems, 
Foster City, CA, USA). Target mRNA expressions were determined according 
to the 2-ΔΔCT method using HPRT as a reference gene. Each primer set is 
shown in Table 1.
II.12. Hp-TLR4 binding assay
To identify the ability of Hp and TLR4 direct interaction, Hp-TLR4 binding 
assay was performed as described previously (Mossman et al., 2008). Briefly, 
high-binding immunoassay plate (Sigma-Aldrich) were coated with BSA, Hp or 
LPS with indicated dose for 24 h at 4°C, and the 2% BSA in PBS added to 
blocking for 1 h. After three washes with PBS containing 0.05% Tween 20, 
TLR4-Fc Fusion protein (2 μg) was added and incubated for 2 h in room 
temperature. The captured TLR4-Fc was detected by using a HRP-conjugated 
goat anti-human IgG Ab (Sigma-Aldrich), and then o-Phnylenediamine 
dihydrochloride (Sigma-Aldrich) was added to read spectrophotometrically at 
450 nm by Multiskan (Thermo Labsystems).
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II.13. Statistical analysis
All quantitative experiments were performed at least in triplicate. Student’s t 
test was used to determine the tow-group comparisons significance. The p-
values less than 0.05 were considered significant.






5'-                            -3' 5'-                          -3'
RANKL TGGAAGGCTCATGGTTGGAT CATTGATGGTGAGGTGTGCA NM_011613.3
OPG TGGAACCCCAGAGCGAAACA GCAGGAGGCCAAATGTGCTG NM_008764.3
IFN-β TGGGAGATGTCCTCAACTGC CCAGGCGTAGCTGTTGTACT NM_010510.1
IFN-γ AGCAAGGCGAAAAAGGATGC TCATTGAATGCTTGGCGCTG NM_008337.4
NFATc1 CCGTTGCTTCCAGAAAATAACA TGTGGGATGTGAACTCGGAA NM_016791.4
c-Fos ACTTCTTGTTTCCGGC AGCTTCAGGGTAGGTG NM_010234.2
c-Fms TCTTCCTCTGTTCCCTTTCAGG AGTTCTGTGAGGACGGGAAC NM_001037859.2
RANK TTCGACTGGTTCACTGCTCC CTGTCGTTCTCCCCCACTTC NM_006529381.2
IFNAR1 CAAGTGTGCCTGGCTTGTTC GTGTACGACAGGCTCTTGCT NM_010508.2
IFNAR2 AGAGCAACCCTTTCTCTGCC GCCAACTCCCAGCAATTATGC NM_010509.2
HO-1 CCTCACAGATGGCGTCACTT GCTGATCTGGGGTTTCCCTC NM_010442.2
HO-2 GTACAGAGAGAGTCGCAGACG AGTAGTTTGTGCTGCCCTCA NM_001136066.2
β-actin CACTGTCGAGTCGCGTCC CGCAGCGATATCGTCATCCA NM_007393.5
Conventional PCR primer sequences
Gene
Sequence GenBank accession 
#Sense Antisense
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Table 1. PCR primers sequences used
III. Results
III.1. Protective effects of Hp on bone.
To understand the pivotal role of Hp in bone microenvironment, bones of 8-
weeks-old wild-type (WT) or Hp-/- male mice were analyzed using micro-
computed tomography (μCT) (n = 6 per group). Bone morphometric analyses 
revealed that the femurs from Hp-/- mice showed significantly lower bone 
volume and trabecula thickness, but increasing trabecular separation than that 
observed in WT mice (Fig. 4A and B). Histological analysis by H&E and TRAP 
staining further revealed that Hp-/- mice exhibited severe loss of bone with 
increased osteoclast formation (Fig. 5A and B). To determine whether RANKL 
induces Hp expression in vivo, soluble RANKL (200 μg per head) was injected 
intraperitoneally in 8-weeks-old male mice (n = 5 per group). Sera were 
collected from mice on day 0, 1, 2, and 3 after RANKL injection and serum Hp 
5'-                            -3' 5'-                           -3'
Hp TCTGGGGTCAGCTTTTTGCT AGCTGCCTTTGGCATCCAT NM_017370.2
TLR2 AAGGAGGTGCGGACTGTTTC AGTCAGGTGATGGATGTCGC NM_011905.3
TLR4 CCCATGCATTTGGCCTTAGC ACTCGGCACTTAGCACTGTC NM_021297.3
TLR7 TGCACTCTTCGCAGCAACTA TCACATGGGCCTCTGGGATA NM_001290755.1
GAPDH TGGAGAAACCTGCCAAGTATGAT CCCTGTTGCTGTAGCCGTAT NM_001289726.1
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levels determined. Serum Hp levels were markedly elevated on day 1 by 
RANKL injection, and were maintained until day 3 (Fig. 6). To further confirm 
the involvement of Hp level elevation in bone quantification, soluble RANKL 
(200 μg per head) was injected to WT or Hp-/- mice (Fig. 7). I observed that Hp 
deficiency significantly provoked RANKL-induced bone resorption in femurs, 
suggesting that Hp has a protective role against RANKL-induced bone 
destruction.
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Figure 4. Hp KO mice showed decreasing of bone mass. The femurs of 8-
weeks-old wild-type (WT) or Hp-/- (Hp KO) male mice were analyzed by μCT
for bone mass (n = 6). (A) The images represent femurs (top) and its trabecular 
bones (bottom) of WT or Hp KO mice. Scale bar is 0.8 mm. (B) Reconstructed 
three-dimensional μCT images were analyzed for measuring bone mass. BV/TV, 
Bone volume/tissue volume; Tb.Th, trabecular thickness; Tb.N, trabecular 
number; Tb.Sp, trabecular separation. *p < 0.05
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Figure 5. Hp KO mice have decreased bone mass with increasing osteoclast 
formation. (A and B) The femurs were investigated by histological sectioning 
and stained with H&E and TRAP, and TRAP-positive osteoclast number was 
counted. *p < 0.05.
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Figure 6. RANKL induced elevation of serum Hp. C57BL/6 mice (8-weeks-
old, n = 5) were intraperitoneally injected with soluble RANKL (200 μg per 
head) for every day, and collected serums with indicated days were analyzed for 
secreted-HP level by using a mouse Hp-specific ELISA (*P < 0.05). d, day.
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Figure 7. Deficiency of Hp induced severe bone loss in RANKL-injection 
model. The mice from WT or Hp KO (8-weeks-olds, n = 5) were 
intraperitoneally injected with soluble RANKL (1 mg/kg) for every day, and the 
femurs were dissected from mice on day 5 after first injection. Reconstructed 
three-dimensional μCT images were analyzed for measuring of quantitative 
bone. BV/TV, Bone volume/tissue volume; Tb.Th, trabecular thickness; Tb.N, 
trabecular number; Tb.Sp, trabecular separation. *p < 0.05
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Figure 8. Administration of Hp increased bone volume in Hp KO mice. The 
mice from Hp KO (8-weeks-olds, n = 6) were daily injected intraperitoneally 
with mHp (1 mg/kg) for 7 days. The femurs were dissected from mice on day 8 
and analyzed by μCT for measuring of quantitative bone. BV/TV, Bone 
volume/tissue volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; 
Tb.Sp, trabecular separation. *p < 0.05
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III.2. The effects of endogenous Hp on osteoclastogenesis
  In the previous results, I observed that absence of Hp showed bone loss 
phenotype with increasing osteoclast formation in vivo. These results raised the 
possibility that Hp might alter osteoclastogenesis directly by affecting 
osteoclast precursor cells to stimulate osteoclast differentiation. To investigate 
whether Hp regulates osteoclast differentiation, I thus primary cultured 
osteoclast precursor cells by extracting BMMs from WT or Hp-/- mice femur 
and tibia. In this study, I observed that RANKL-induced osteoclast 
differentiation was not affected by deletion of Hp (Fig. 8A). I next examined 
the effect of Hp-/- on key transcription factors for osteoclastogenesis, c-Fos and 
NFATc1, by western blotting. As shown in Fig. 8B, RANKL-stimulation 
induced an upregulation of c-Fos and NFATc1 expression during the osteoclast 
differentiation period, but no difference was shown between WT and Hp-/-
BMMs. Indeed, expressions of Hp during M-CSF and RANKL induced-
osteoclastogenesis were not detected in my culture system (data not shown). 
Collectively, these results indicated that endogenous expression of Hp did not 
affected RANKL-induced osteoclast differentiation.
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Figure 9. Deficiency of Hp did not affected on RANKL-induced 
osteoclastogenesis. Primary cultured BMMs from WT or Hp KO mice were 
induced osteoclast differentiation by stimulation of RANKL (100 ng/ml) in the 
presence of M-CSF (60 ng/ml) for 4 days. (A) Appeared osteoclasts were 
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stained for TRAP (left), and three or more nuclei-containing osteoclast were 
counted. (B) Culturing of BMMs in the indicated days were lysed and subjected 
to Western blotting with the specific antibodies. RL, RANKL; d, day.
III.3. Treatment of Hp inhibits osteoclast differentiation. 
I next addressed the question of whether treatment with Hp affects osteoclast 
differentiation. To determine the effects of Hp on osteoclastogenesis, BMMs 
were cultured with PBS or various indicating doses of Hp in the presence of M-
CSF and RANKL for 4 days. TRAP staining revealed that RANKL-induced 
osteoclast differentiation was gradually inhibited by increasing Hp dose (Fig. 
9A and B). To further ascertain the biological potency of Hp against the survival 
of osteoclast precursor cells, BMMs were treated with various doses of Hp in 
the presence of M-CSF for the number of days indicated. As shown in Figure 
9C, stimulation with Hp did not affected cells’ survival during the M-CSF-
induced cell growth period. These data suggested that Hp has inhibitory effects 
on RANKL-induced osteoclast differentiation without altering cells’ survival. 
Osteoclastogenesis is a multiple step process that includes proliferation of 
osteoclast precursors, cell fusion, and osteoclast activation (maturation). To 
determine the precise step of osteoclast differentiation targeted by Hp, I treated 
BMMs with Hp at different time points during RANKL-induced 
osteoclastogenesis and analyzed osteoclast formation on day 4 using TRAP-
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staining (Fig. 10). As shown in Figure 10A and B, simultaneous treatment of Hp 
with M-CSF and RANKL on the first day did not lead to effective osteoclast 
formation, whereas treatment with Hp on the second or on the third day after 
RANKL stimulation did not altered osteoclast formation. These results suggest 




Figure 10. Hp treatment inhibits osteoclast differentiation. (A and B) 
BMMs were cultured with PBS or the indicated dose of Hp in the presence of 
M-CSF (60 ng/ml) and RANKL (100 ng/ml). After culturing for 4 days, (A) 
appeared osteoclasts were stained for TRAP, (B) and TRAP-positive three or 
more nuclei-containing osteoclasts were counted. *p < 0.05. (C) BMMs were 
cultured with various doses of Hp in the M-CSF (60 ng/ml). After indicated 
days culturing, cell viability was measured. d, day.
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Figure 11. Treatment of Hp inhibits RANKL-induced osteoclast 
differentiation at early stage. (A and B) Hp was treated at indicated time 
periods during RANKL-induced osteoclastogenesis. After 4 days of culturing, 
the cells were fixed and stained for TRAP (top), and appeared TRAP-positive 
three or more nuclei-containing osteoclasts were counted (bottom). *p < 0.05.
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III.4. Hp inhibits RANKL-induced c-Fos expression
Since reduced-osteoclast number results in inhibitory effects on osteoclast 
differentiation, it is crucial to know how the extracellular stimuli lead to the 
activation of key transcription factor responsible for this process. To understand 
the molecular mechanism by which Hp regulates RANKL-induced osteoclast 
differentiation, I explored the effects of Hp on the expression of the key 
transcription factors, c-Fos and its downstream factor NFATc1 using western 
blotting. In the presence of M-CSF and PBS, stimulation of RANKL 
stimulation induced the upregulation of c-Fos and NFATc1 during the osteoclast 
differentiation period (Fig. 11). However, treatment with Hp significantly 
inhibited RANKL-induced c-Fos and NFATc1 protein expression. To further 
understand how the transcription factors were affected by Hp treatment, mRNA 
expression was analyzed using real-time PCR. mRNA expressions of the
RANKL receptor RANK and M-CSF receptor c-Fms was not altered by Hp 
stimulation (Fig. 12). Interestingly, Hp stimulation did not affected c-Fos 
mRNA expression whereas its protein expression was completely blocked by 
Hp treatment. Furthermore, NFATc1, the downstream transcription factor of c-
Fos, was considerably inhibited by Hp treatment. These results suggest that the 
inhibitory role of Hp might be mediated via the proteasomal degradation of c-
Fos during RANKL-induced osteoclast differentiation.
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Figure 12. Treatment of Hp inhibited RANKL-induced c-Fos and NFATc1 
expression. BMMs were cultured in the presence of M-CSF (60 ng/ml) alone or 
RANKL (RL; 100 ng/ml) together with PBS or Hp (20 μg/ml) for the indicated 
days. Total cell lysates were harvested and subjected to Western blotting with 
the indicated antibodies. d; day.
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Figure 13. Hp did not affect mRNA expression of c-Fos. BMMs were 
cultured for the indicated times in the presence of M-CSF (60 ng/ml) alone or 
RANKL (RL; 100 ng/ml) together with stimulation of PBS or Hp (20 μg/ml). 
Total RNA was isolated, and the mRNA expression of RANK, c-Fms, c-Fos and 
NFATc1 were analyzed by real-time PCR with β-actin mRNA as an endogenous 
control. *p < 0.05.
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III.5. Hp inhibits c-Fos-dependent osteoclastogenesis
  Previous results showed that treatment with Hp significantly suppressed 
osteoclast differentiation through downregulation of c-Fos and NFATc1 
expression. To investigate whether the reduction in c-Fos and NFATc1 
expression is mediated by an Hp-induced anti-osteoclastogenic effect, BMMs 
were overexpressed with pMX-IRES-FLAG-empty (Empty) or pMX-IRES-
FLAG-constitutively active form of c-Fos (CA-c-Fos) and constitutively active 
form of NFATc1 (CA-NFATc1) using a retroviral infection system (Fig. 13A). 
In this study, the Hp-induced inhibitory effect in osteoclast differentiation was 
fully reversed by the forced expression of CA-c-Fos or CA-NFATc1 (Fig. 13B 
and C). As c-Fos upregulates its downstream transcription factor NFATc1 
expression, I next explored whether the overexpression of CA-c-Fos affects 
NFATc1 expression. As shown in Figure 14, forced expression of CA-c-Fos 
recovered NFATc1 expression in the presence of Hp treatment. These results 
suggest that Hp exerts its anti-osteoclastogenesis effects through the inhibition 
of c-Fos expression.
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Figure 14. Overexpression of CA-c-Fos or CA-NFATc1 abolished the 
inhibitory effect of Hp in osteoclastogenesis. (A-C) BMMs were transduced 
with pMX-FLAG-empty (Empty) or pMX-FLAG-constitutively active form of 
c-Fos (CA-c-Fos) or pMX-FLAG-constitutively active form of NFATc1 (CA-
NFATc1) respectively by retroviral infection. (A) The cell lysates from 
transduced BMMs were subjected to Western blotting. (B and C) The 
transduced BMMs were further cultured 4 days with PBS or Hp (20 μg/ml) in 
the presence of M-CSF (60 ng/ml) and RANKL (100 ng/ml) to generated 
osteoclasts. The appeared osteoclasts were then stained for TRAP, and TRAP-
positive three or more nuclei-containing osteoclasts were counted. *p < 0.05.
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Figure 15. Hp-induced suppression of NFATc1 was recovered by 
overexpression of CA-c-Fos. The transduced BMMs with pMX-FLAG-empty 
(Empty) or pMX-FLAG-constitutively active form of c-Fos (CA-c-Fos) were 
further cultured with or without RANKL (100 ng/ml) and Hp (20 μg/ml) in the 
presence M-CSF (60 ng/ml). After culturing for 24 h, the cells were lysed and 
total cell lysates were subjected to Western blotting with the indicated 
antibodies.
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III.6. Hp does not alter MAPKs and NF-κB signaling pathway
In the previous data, I observed that Hp-induced inhibitory effects against 
osteoclastogenesis is caused by suppression of c-Fos expression. These results 
led me to hypothesized that Hp may regulates upstream signaling of c-Fos. 
Previous studies revealed that RANKL-induced c-Fos expression is mediated 
by MAPKs and NF-κB signaling pathway (Boyce et al., 2015; Soysa et al., 
2012). To find the mechanism of Hp-mediated regulation of c-Fos, I 
investigated the activation of MAPKs signaling pathways upon RANKL 
stimulation. RANKL-induced activation of ERK, JNK, and p38 were rapidly 
phosphorylated within 30 min (Fig. 15A). However, pre-treatment of Hp did not 
altered RANKL-induced activation of them. In addition, it is well known that 
AKT-mediated NFATc1 induction is independent of c-Fos during RANKL-
induced osteoclast differentiation (Moon et al., 2012). As I expected, treatment 
of Hp did not affected RANKL-induced AKT phosphorylation (Fig. 15A).
Meanwhile, c-Fos expression also induced by canonical NF-κB signaling 
through RANKL-induced phosphorylation and degradation of Inhibitor of 
kappa B (IκB), which in turn permits releasing of P65/P50 heterodimers for 
translocation in nucleus and transcription its target genes (Boyce et al., 2015).
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To ascertain whether Hp-induced suppression of c-fos is involved in NF-κB
signaling, I investigated the activation of canonical NF-κB signaling during 
RANKL stimulation (Fig. 15B). However, treatment of Hp did not affect P65 
and IκB phosphorylation when I compared to that of PBS treatment. These 
results suggest that Hp-induced suppression of c-Fos expression is not mediated 
by MAPKs, AKT, and canonical NF-κB signaling pathway.
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Figure 16. Treatment of Hp did not affect7 MAPKs, AKT, and canonical
NF-κB signaling pathway. (A and B) BMMs were cultured for 24 h in the 
presence of M-CSF (60 ng/ml). After culturing, BMMs were serum- and 
cytokine-starved in the presence of PBS or Hp (20 μg/ml) for 1 h and then 
stimulated with RANKL (100 ng/ml) for the indicated time. Total cells were 
lysed and subjected to Western blotting to detect target proteins expression.
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III.7. Hp induces IFNβ expression to inhibit c-Fos expression and 
osteoclastogenesis
During this study to identify the exact mechanism of regulation of c-Fos by 
Hp, I noted that the RANKL-induced MAPKs, AKT, and NF-κB signaling 
pathways were not involved and the evidence was insufficient to conclude that 
Hp-induction completely blocks c-Fos expression. Furthermore, mRNA 
expression of c-Fos was not altered by Hp stimulation. Thus, I speculated that 
Hp-induced suppression of c-Fos protein expression level might be due to 
proteasomal degradation. Indeed, it is well established that IFNβ has a 
remarkable inhibitory effect on osteoclastogenesis via selectively and dramatic 
downregulation of c-Fos protein expression (Takayanagi et al., 2002b). To 
ascertain whether the inhibitory action of Hp is mediated through IFNβ
induction, mRNA expression of IFNβ and secreted-IFNβ were analyzed. As 
expected, Hp treatment resulted in significant elevation of IFNβ levels (Fig. 
16A and B). However, IFNγ, also known as an osteoclastogenesis suppressor as 
it degrades TRAF-6, was not affected (Takayanagi et al., 2000). To address 
whether the Hp-mediated suppression of c-Fos was indeed caused by IFNβ, I 
next examined c-Fos expression recovery by using a IFNβ-specific neutralizing 
antibody. I observed that Hp-induced suppression of c-Fos and NFATc1 
expression was substantially rescued by IFNβ neutralizing antibody (Fig. 17). 
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In line with this, I next investigated whether Hp induces IFNβ expression 
during RANKL-induced osteoclastogenesis. Although Hp-induced IFNβ mRNA 
expression was gradually decreased by RANKL-induced osteoclast 
differentiation, expression of IFNβ was higher than that observed following 
PBS treatment (Fig. 18). In addition, I found that blocking of IFNβ substantially 
suppressed the inhibitory effects of HP; however, it is still remained to have
insufficient effects of IFNβ blocking to fully recover osteoclastogenesis (Fig. 
19). Therefore, BMMs from WT or IFN receptor 1 knockout mice (IFNAR1-/-) 
were isolated and differentiated into osteoclasts. Interestingly, the inhibitory 
effects of Hp against RANKL-induced osteoclastogenesis was fully abolished 
in IFNAR-/- BMMs (Fig. 20A). Furthermore, I found that treatment with Hp 
increased mRNA expression of IFNAR1 and IFNAR2 (Fig. 20B). These data 
suggested that Hp exerts its anti-differentiation effect through Hp-induced 
autonomous regulation of IFNβ.
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Figure 17. Hp induced IFNβ expression. (A and B) BMMs were cultured with 
PBS or Hp (20 μg/ml) in the presence of M-CSF (60 ng/ml). After culturing for 
24 h, (A) total RNA was isolated and mRNA expression levels of IFNγ and 
IFNβ were analyzed by real-time PCR (left and middle). *p < 0.05. (B) The 
secreted-IFNβ production from supernatant of BMMs were measured. *p < 0.05.
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Figure 18. IFNβ blocking rescued Hp-induced suppression of c-Fos and 
NFATc1 expression. BMMs were cultured with indicated RANKL (100 ng/ml) 
and Hp (20 μg/ml) and specific-IFNβ neutralizing antibody (10 and 20 μg/ml)
in the presence of M-CSF (60 ng/ml). After culturing for 24 h, the cells were 
lysed and total cell lysates were subjected to Western blotting with indicated 
antibodies.
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Figure 19. Hp induced IFNβ expression during RANKL-induced 
osteoclastogenesis. BMMs were cultured with PBS or Hp (20 μg/ml) in the 
presence of M-CSF (60 ng/ml) with or without RANKL (100 ng/ml). After 
culturing of indicated time, total RNA was isolated and analyzed mRNA 
expression by real-time PCR. *p < 0.05. RL; RANKL, d; day.
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Figure 20. Blocking of IFNβ rescued inhibitory effects of Hp in osteoclast 
differentiation. BMMs were cultured with PBS or Hp (20 μg/ml) and irrelevant 
normal mouse IgG (10 μg/ml) or specific-IFNβ neutralizing antibody (10 μg/ml) 
in the presence of M-CSF (60 ng/ml) and RANKL (100 ng/ml). After culturing 
for 4 days, the cells were fixed and stained for TRAP (left). Appeared TRAP-
positive osteoclasts that contained three or more nuclei were counted (right). **p 
< 0.01, *p < 0.05.
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Figure 21. Inhibitory effects of Hp against osteoclastogenesis abolished in 
IFNAR KO BMMs. Isolated BMMs from WT or IFNAR KO mice’s tibia were 
cultured for 24 h. (A) Total RNA was isolated and the expression levels of 
target mRNA were analyzed by RT-PCR. (B) WT or IFNAR KO BMMs were 
cultured with PBS or Hp (20 μg/ml) in the presence of M-CSF (60 ng/ml) and 
RANKL (100 ng/ml). After culturing for 4 days, the cells were fixed and 
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stained for TRAP. Appeared TRAP-positive cells containing three or more 
nuclei were counted (right). *p < 0.05.
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III.8. Induction of IFNβ is not mediated by Hb 
  Meanwhile, it is well established that biological function of Hp mainly 
attributes to interaction with Hb, then complexes of Hp-Hb bind to CD163 on 
macrophage for clearance of Hb-induced cell’s cytotoxicity (Kristiansen et al., 
2001; Tseng et al., 2004). In addition, there was no binding to CD163 detected 
in case of non-complexed Hb nor Hp alone. This raised the possibility that FBS 
containing Hb might be involved IFNβ expression through Hb-Hp complexes.
Thus, I next examined the effect of Hp with Hb treatment on BMMs. Serum-
free cultured BMMs showed increasing of IFNβ mRNA expression by Hp 
treatment, whereas treatment of Hb alone or Hb-Hp together reduced IFNβ (Fig 
21A). Furthermore, Hb-Hp-CD163 complexes-induced mRNA expression of 
heme oxygenase 1 (HO-1) was not affected when I treated that with Hp alone 
(Fig 21B). These results suggest that Hp-induced IFNβ expression is not 
mediated by CD163 binding with Hp-Hb complexes.
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Figure 22. Hp-induced IFNβ expression was not mediated by Hb. (A and B) 
BMMs were cultured with M-CSF (60 ng/ml). After culturing for 24 h, the cells 
detached and exchanged with serum-free α-MEM with Hb (10 μg/ml) or Hp (20 
μg/ml) or Hb and Hp together. The cells were further cultured for 24 h and total 
RNA isolated and mRNA expression levels of IFNβ and HO-1 were analyzed 
by real-time PCR. *p < 0.05.
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III.9. Hp induces IFNβ via TLR4 
It is well established that induction of IFNβ is mediated through several Toll-
like receptors (TLRs), including TLR2, 3, 4, 7, 8 and 9 (Aubry et al., 2012; 
Noppert et al., 2007). In order to identify Hp-binding receptor, I next explored 
whether several TLRs-KO BMMs, such as TLR2, TLR4, and TLR7 affect Hp-
induced inhibitory effects on osteoclast differentiation. As shown in Figure 22A, 
deleted each gene, TLR2, TLR4, and TLR7 did not affected the other TLRs 
mRNA expression. Interestingly, TRAP-staining showed that inhibitory effects 
of Hp on osteoclastogenesis completely abolished on TLR4-deleted BMMs (Fig. 
22B and C). Consistent with this results, I observed that induction of IFNβ
mRNA expression by Hp was completely blocked on TLR4 knockout BMMs
(Fig. 22D). To verify inhibitory effects of Hp on osteoclastogenesis due to the 
IFNβ, treatment of neutralizing antibody against IFNβ substantially rescued the
Hp-induced suppression of osteoclastgenesis even on TLR2 or TLR7 KO 
BMMs (Fig. 23).
Since the IFNβ has a remarkable downregulation of c-Fos protein expression 
(Takayanagi et al., 2002b), I next investigated whether TLR4 was related to Hp-
induced c-Fos suppression. As shown in Figure 24, Hp-induced suppression of 
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c-Fos and its downstream transcription factor NFATc1 were completely 
recovered in TLR4 KO BMMs. In addition to the effects of TLR4 deletion, 
blocking of TLR4 by its specific neutralizing antibody treatment also abolished 
Hp-induced suppression of osteoclastogenesis (Fig. 25). These results indicated 
that Hp suppresses osteoclastogenesis via TLR4-IFNβ signaling axis.
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Figure 23. Inhibitory effects of Hp on osteoclastogenesis abolished on
TLR4 KO BMMs. (A) Each BMMs, obtained from WT, TLR2 KO, TLR4 KO, 
and TLR7 KO mice were cultured for 24 h in the presence of M-CSF (60 
ng/ml). After culturing, total RNA was isolated and mRNA expression levels of 
TLR2, TLR4, TLR7, and GAPDH were analyzed by conventional PCR. *p < 
0.05. (B and C) The cells were cultured with PBS or Hp (20 μg/ml) in the 
presence of M-CSF (60 ng/ml) and RANKL (100 ng/ml) for 4 days. After 
culturing, the cells were fixed and stained for TRAP. (C) Appeared TRAP-
positive cells containing three or more nuclei were counted *p < 0.05. (D) Each 
BMMs cells were cultured with PBS or Hp (20 μg/ml) in the presence of M-
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CSF (60 ng/ml) for 24 h. Then total RNA was isolated, and the expression of 
IFNβ mRNA was analyzed by real-time PCR with β-actin mRNA as an 
endogenous control. *p < 0.05.
Figure 24. Inhibitory effect of Hp was abolished by IFNβ-neutralizing 
antibody on TLR2 KO or TLR7 KO BMMs. TLR2-/- or TLR7-/- BMMs were 
cultured with PBS or Hp (20 μg/ml), and irrelevant normal mouse IgG (10 
μg/ml) or specific-IFNβ neutralizing antibody (10 μg/ml) in the presence of M-
CSF (60 ng/ml) and RANKL (100 ng/ml). After culturing for 4 days, the cells 
were fixed and stained for TRAP, and the cells containing three or more nuclei 
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were counted. *p < 0.05.
Figure 25. Hp did not affect c-Fos and NFATc1 expression in TLR4 KO 
cells. WT or TLR4 KO BMMs were cultured with PBS or Hp (20 μg/ml) with 
or without RANKL (100 ng/ml) in the presence of M-CSF (60 ng/ml). After 
culturing for 24 h, the cells were lysed and total cell lysates were subjected 
Western blotting with indicated antibodies.
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Figure 26. Blocking of TLR4 inhibited Hp-induced suppression of 
osteoclastogenesis. BMMs were cultured with PBS or Hp (20 μg/ml) and 
irrelevant normal mouse IgG (10 μg/ml) or specific-TLR4 neutralizing antibody 
(10 μg/ml) in the presence of M-CSF (60 ng/ml) and RANKL (100 ng/ml) for 4 
days. After culturing for 4 days, the cells were fixed and stained for TRAP (left), 
and TRAP-positive cells containing three or more nuclei were counted (right). 
*p < 0.05.
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III.10. Hp directly binds to TLR4
  Since I established that Hp negatively regulates osteoclastogenesis via TLR4, 
I next investigated whether Hp regulates TLR4 expression. Interestingly, Hp 
significantly downregulates TLR4 expression (Fig. 26A). In contrast, mRNA 
expression of TLR4 was elevated by treatment with Hp during RANKL-
induced osteoclastogenesis (Fig. 26B). These results suggested that TLR4 might 
be involved in Hp-induced degradation. Indeed, it is well known that activation 
of the TLR4 by binding of ligands, such as LPS, initiates endocytosis of TLR4 
with signal transduction, and leads to lysosomal degradation (Husebye et al., 
2006; Noppert et al., 2007). Therefore, I proceeded to examine the
identification of the Hp-induced molecular recognition events that determines
the TLR4 expression in the plasma membrane. Incubation with LPS or Hp 
induced a gradual decrease in the level of TLR4 in the plasma membrane (Fig. 
27). I also analyzed whether Hp and TLR4 colocalized in the plasma membrane 
at the early stages, i.e., before the internalization of Hp-TLR4 complexes. 
Analysis using confocal images of FITC-labelled Hp revealed colocalization 
with TLR4 within 60 min of treatment (Fig. 28). To determine whether Hp can 
directly bind to TLR4, I next performed a Hp-TLR4 binding assay using
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recombinant TLR4 fused to the human Fc fragment of IgG1. As shown in figure 
29, dose-dependent binding of immobilized Hp was observed, as LPS bound to 
TLR4 in a dose dependent manner. These observations suggest that Hp directly 
bind to TLR4 to induced intracellular signal transduction.
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Figure 27. Hp suppressed TLR4 protein expression. (A and B) BMMs were 
cultured with PBS or Hp (20 μg/ml) with the M-CSF (60 ng/ml) alone or 
RANKL (100 ng/ml) together for indicated day. The samples were harvested 
and subjected to Western blotting or real-time PCR to measure TLR4 
expression levels. *p < 0.05.
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Figure 28. Hp induced TLR4 internalization. BMMs were cultured with M-
CSF (60 ng/ml). After culturing for 24 h, the cells were incubated with PBS, Hp
(20 μg/ml), and LPS (1 μg/ml) respectively. After incubation for indicated time, 
the cells were detached and analyzed cell surface-TLR4 by flow cytometry. *p < 
0.05.
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Figure 29. Hp colocalized with TLR4. BMMs were cultured in presence of M-
CSF (60 ng/ml). After culturing for 24 h, the cells were incubated with Hp-
FITC (green) for indicated times. The cells then fixed, and stained with TLR4 
Ab (green) with DAPI staining for nuclei (blue).
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Figure 30. Hp directly binds to TLR4. High-binding immunoassay plate were 
coated with indicated dose of BSA, Hp, and LPS respectively. Immobilized 
each protein was then incubated with 2 μg of TLR4-Fc fusion protein. Binding 
ability with TLR4 was measured by HRP-conjugated anti-human IgG, then read 
spectrophotometrically at 450 nm.
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III.11. The role of Hp in osteoblasts
In the bone environment, osteoclast differentiation is regulated by RANKL-
expressing osteoblasts. Under pathological condition, several factors, such as 
IL-1α, IL-6, TNFα and LPS, have been shown to promote RANKL expression
while decreasing its decoy receptor OPG in osteoblasts (Collin-Osdoby et al., 
2001; Weitzmann, 2013). Thereby, this condition promotes osteoclast
differentiation by coupling with RANKL-expressed osteoblasts. However, the 
role of Hp in osteoblast differentiation is poorly understood. Prior to the
investigation of relationship between Hp and osteoblast-osteoclast coupling, I 
first examined the effects of Hp on osteoblast differentiation. ALP and alizarin 
red staining showed that treatment of Hp with various doses did not affected 
osteogenesis in calvarial osteoblasts (Fig. 30A). In addition, mRNA expression 
for ALP and OCN also was not affected by Hp (Fig. 30B). I next confirmed the 
effect of deletion of endogenous Hp in osteoblast differentiation. However, I 
observed that osteoblasts from Hp-/- mice did not affect not only in ALP and 
alizarin red staining, but also in ALP and OCN mRNA expression, from WT 
mice (Fig. 31A and B). I investigated the effects of Hp on IL-1α induced 
osteoclastogenesis by co-culturing with osteoblasts and BMMs. As expected, 
Hp-induced inhibitory effects were dose-dependent (Fig. 32A), whereas IFNβ
mRNA expression was elevated (Fig. 32A). Indeed, I observed that osteoblasts
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did not expressed IFNβ following Hp treatment (data not shown). These results 
indicated that Hp exerts inhibitory effects on IL-1α induced by indirect 
osteoclast differentiation via increasing of IFNβ in BMMs. However, Hp could 
reduce RANKL in IL-1α-treated osteoblasts. Thus, I next examined the effect of 
Hp on RANKL expression in osteoblasts. As shown in figure 33, IL-1α induced 
upregulation of RANKL whereas downregulation of OPG did not altered Hp 
treatment. Consistent with these results, I next checked the expression of Hp by 
stimulating various factors. Interestingly, several factors, including IL-1α, 
TNFα, and LPS induced Hp mRNA expression, partially effecting VD3, but not 
effect on BMP-2 (Fig. 34A). Furthermore, the amount of secreted Hp was 
increased in the cultured supernatants of osteoblasts in the presence of IL-1α or 
TNFα (Fig. 34B). These results raised the possibility that inflammatory factors-
induced Hp production from osteoblasts may have a negative effect on
osteoclastogenesis. To determine whether osteoclast differentiation was 
regulated by IL-1α-induced Hp expression in osteoblasts, I co-cultured WT or 
Hp-/- osteoblasts with BMMs. Importantly, IL-1α-induced osteoclast formation 
was significantly higher in Hp-/- osteoblasts than in WT osteoblasts (Fig. 35A). 
Similarly, the IL-1α-induced RANKL/OPG ratio was not altered in Hp-/-
osteoblasts, whereas IFNβ was significantly downregulated in Hp-/- osteoblast. 
Collectively, these results indicated that secreted-Hp from osteoblasts
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negatively regulates osteoclastogenesis to inhibit excessive osteoclast formation.
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Figure 31. Treatment of Hp did not affect osteogenesis. (A and B) Calvarial
osteoblasts were cultured in osteogenic media containing 10 mM β-
glycerophosphate, 50μg/ml ascorbate-2-phosphate, and the 100 ng/ml of BMP-
2 with indicated dose of Hp. (A) After culturing for 3 days, the cells were 
stained for ALP (top). Alizarin Red S staining was performed on day 9 (bottom). 
(B) After treatment of osteogenic media, mRNA expression for ALP or OCN 
were analyzed on day 3 or 7 respectively.
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Figure 32. Deletion of Hp did not affect osteogenesis. (A and B) Calvarial 
osteoblasts were isolated from WT of Hp KO new born mice. (A) After 
culturing the cells with osteogenic media for 3 days, ALP staining was 
performed (top). Further cultured osteoblast with osteogenic media were stained 
for Alizarin Red S on day 9 (bottom). (B) After treatment of osteogenic media, 
mRNA expression for ALP or OCN were analyzed on day 0, 1, 3, and 7 by real-
time PCR. 
71
Figure 33. Hp inhibited osteoclastogenesis in co-culture system. (A and B)
The co-culture of BMMs and osteoblast was performed in the presence of IL-1α
(20 ng/ml) for 9 days. Appeared osteoclasts were stained for TRAP (A) or RNA 
was isolated from total cells to measure IFNβ mRNA expression. *p < 0.05.
72
Figure 34. Stimulation of Hp did not affect IL-1α -induced RANKL and 
OPG expression. Osteoblasts were cultured with indicated dose of Hp in the 
presence of PBS or IL-1α (20 ng/ml) for 24 h. After culturing, total RNA was 
isolated and analyzed mRNA expression for RANKL and OPG by real-time 
PCR.
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Figure 35. Inflammatory cytokines induced Hp secretion in osteoblast. (A 
and B) Osteoblasts were cultured with treatment of PBS, VD3 (10 nM), IL-1α
(10 ng/ml), TNFα (10 ng/ml), LPS (10 ng/ml), and BMP2 (100 ng/ml) 
respectively. (A) After culturing for 24 h or 48 h, total RNA was extracted and 
analyzed mRNA expression with indicated specific primers. (B) After culturing 
for 24 h or 48 h, supernatant medium was collected and measured secreted Hp 
by use of ELISA. 
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Figure 36. Absence of Hp provoked excessive osteoclast formation. (A)
WT or Hp KO osteoblasts were cocultured with BMMs in the presence of PBS 
or IL-1α (20 ng/ml) for 9 days. After culturing, the cells were fixed and stained 
for TRAP to measure osteoclast number (left). And TRAP-positive cells 
containing three or more nuclei were counted (right). (B, C, and D) WT or Hp 
KO osteoblasts were cocultured with BMMs in the presence of PBS or IL-1α
(20 ng/ml) for 1 days. Total RNA was extracted and analyzed mRNA 
expression for RANKL, OPG, and IFNβ by use of real-time PCR. *p < 0.05.
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IV. Discussion
Hp was initially identified as one of the acute phase plasma proteins that 
interacts with Hb. Therefore, evidence has accumulated for a role of Hp binding
with extracellular Hb, allowing detoxification of Hb-mediated tissues damage,
including vascular, liver, kidney, and spleen damage (Schaer et al., 2013). 
Understandably, it is apparent that Hp is capable of blocking the action of Hb-
induced tissues damages; however, I focused on Hp-mediated intracellular 
signaling during RANKL-induced Osteoclastogenesis and its key role in bone 
protection properties. 
In the RANKL-administration animal model, I observed a simultaneously
increasing levels of serum Hp and bone destruction (Fig. 6 and 7). This
phenomenon raised the possibility that RANKL-induced elevation of Hp may 
contributes to bone destruction. However, Hp-/- mice showed severe bone loss,
whereas administration of Hp increased bone volume (Fig. 4 and 8). Insight into 
the physiological actions of Hp suggested that Hp participates to compensate in 
RANKL-induced excessive osteoclast formation, and leads to bone destruction. 
Importantly, previous reports showed that reduced bone mass density is 
associated with hemolysis in patients with sickle cell diseases (Baldanzi et al., 
2011). Indeed, it is well-known that oxidative stress-ROS, and intravascular 
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hemolysis activation over its clearance provoked sickle cell disease (Schaer et 
al., 2013). Therefore, I speculated that Hp might be involved in indirect 
regulation of osteoclast differentiation by Hb-induced ROS production blocking,
and this proposal was supported by previous reports that ROS stimulates
RANKL-induced osteoclast differentiation (Ha et al., 2004; Lee et al., 2005). 
However, I observed that the treatment of Hp directly reduced osteoclast 
differentiation at early stage (Fig. 10), but not in the late stage. This observation 
suggested that stimulation of Hp induces immune events in BMMs rather than 
in RANKL-induced osteoclast differentiation. Similarly, it is well-known that 
LPS inhibits osteoclast differentiation by TLR4 receptor stimulation, 
consequently activating immune responses to prevent pathogenic effects 
(Takami et al., 2002; Zou and Bar-Shavit, 2002). In contrast, LPS induces 
osteoclast differentiation indirectly in an osteoblast co-culture system by 
stimulating RANKL expression in osteoblast (Sato et al., 2004). Therefore, LPS 
has been used predominantly to induce osteoporosis in animal models (Hussain 
Mian et al., 2008; Orcel et al., 1993; Sakuma et al., 2000). Importantly, I 
observed that treatment with Hp did not alter RANKL expression in osteoblasts
(Fig. 33). In addition, Hp inhibited IL-1α- induced osteoclast differentiation in 
co-culture system without changing the level of RANKL and OPG expression
(Fig. 35). Although LPS-induced RANKL expression is mediated via TLR4-
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MyD88 signaling axis in osteoblasts (Sato et al., 2004), I suggested that Hp-
mediated receptor activation in osteoblast is ineffective or modulated by 
another unknown receptor. 
It is well established that inflammatory factors, IL-1 and IL-6 stimulate 
Haptoglobin production in hepatocyte (Prowse and Baumann, 1989). Recent 
studies also revealed that inflammatory cytokines upregulate Hp mRNA 
expression in mature adipocytes (do Nascimento et al., 2004; Friedrichs et al., 
1995), and keratinocyte cell line HaCaT (Xia et al., 2008). In this study, I 
observed that stimulation of inflammatory cytokines, such as IL-1α and TNFα
significantly induce Hp expression in osteoblasts (Fig. 34). Although deletion of 
or treatment with Hp did not affected osteogenesis (Fig. 30 and 31), these 
results indicated that osteoblasts that originated from mesenchymal stem cells 
(MSCs) participate in immune response indirectly through the secretion of Hp
and in turn IFNβ production in BMMs. Previous studies have reported that 
expression of IFNβ is expressed in response to the several TLRs activation, 
including TLR2, 3, 4, 7, 8 and 9 in macrophages (Aubry et al., 2012; Noppert et 
al., 2007). In this study, I found that deletion of TLR4 abolished Hp-induced 
IFNβ expression (Fig. 22). Indeed, IFNβ is one of the type I IFNs, effectively
expressed at local sites in an autocrine manner via its receptor IFNAR (Noppert 
et al., 2007). In agreement with the previous finding, I first observed that Hp 
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treatment during RANKL-induced osteoclastogenesis showed significant 
induction of IFNβ expression (Fig. 18). Furthermore, treatment with IFNβ
neutralizing antibody or deletion of IFNβ receptor showed substantially 
abrogation of inhibitory effects of Hp in osteoclastogenesis (Fig. 19). These 
results indicate that secreted IFNβ regulates osteoclastogenesis in an
autonomous manner. Interestingly, treatment of Hp decreased protein 
expression of TLR4 while increasing its mRNA expression (Fig. 26). Harald H. 
et al. has shown that LPS stimulation induced TLR4 trafficking to lysosomes 
for degradation (Husebye et al., 2006). With regard to binding ability to TLR4, I 
observed that the level of cell surface TLR4 was decreased by Hp treatment 
(Fig. 27). Similarly, previous reports showed that upon ligand binding, TLR4 
internalizes into endosomes to induce signal transduction by the myeloid 
differentiation primary response gene 88 (MyD88)-independent pathway, then 
activates TIR-domain-containing adapter-inducing IFN-β (TRIF) mediated 
interferon expression (Gomez et al., 2015; Rajaiah et al., 2015). Therefore, 
internalization of TLR4 from cell surface is necessary to induce IFN-β
expression via intracellular signaling activation as I observed. Although, 
confocal images showed co-localization (Fig. 28), it was unclear whether they
interact directly. There is a possibility that the close location of Hp and TLR4 
can cause rapid internalization with degradation. Eventually, I found that the 
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dose-dependent binding of immobilized Hp to TLR4 as LPS binding to TLR4
(Fig. 29). 
Numerous factors that regulate bone homeostasis are well established (Sims 
and Martin, 2014). Therefore, this study demonstrates that inflammatory 
cytokine-induced Hp secretion in osteoblasts mediates osteoprotective signals 
that limit excessive osteoclast formation by coupling with osteoclasts (Fig. 35
and 36).
Consistent with Hp playing a role in anti-osteoclast effects, the fundamental 
role of Hp is to prevent Hb-induced oxidative stress and inflammation. Indeed, 
human plasma-derived Hp was approved for the treatment of hemolysis, burn 
injuries, and massive blood transfusions with trauma in 1985 (Schaer et al., 
2013). From a biological standpoint, aging showed that processes of 
osteogenesis and chondrogenesis are reduced during aging while enhancing 
osteoclastogenesis and adipogenic potential (Cao et al., 2005; Moerman et al., 
2004; Zheng et al., 2007). Importantly, Wilson A et al. showed that aging 
significantly down-regulated Hp transcription in mice-bone marrow derived 
MSCs (8 to 26 month) (Wilson et al., 2010). This report implies that MSCs 
express Hp, which is down regulated during aging in bone marrow. Although 
treatment of Hp to block exorbitant osteoclast activation has not been studied 
until now, I suggest that Hp is may be clinically useful for protection of bone 
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from excessive osteoclast activation during aging.
In conclusion, this study unveils a pivotal role of Hp that is secreted by 
inflammation stimulated-osteoblast, which in turn activates BMMs to produce 
anti-inflammatory cytokine IFNβ, leading to autonomous regulation of IFNβ
that suppresses osteoclast differentiation by TLR4-IFNβ-IFNAR signaling axis. 
Therefore, I propose that Hp-mediated osteoblast and osteoclast coupling plays 
a fundamental role in bone protection from excessive osteoclast differentiation. 
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Figure 37. Schematic model of the protective role of Hp on 
inflammation-induced osteoclastogenesis. Inflammatory cytokines, such as 
IL-1, TNFα, and LPS stimulate RANKL induction to generate osteoclast 
differentiation via their receptors RANK-c-Fos-NFATc1 signaling axis. 
Concurrently secretion of Hp from osteoblast restricts excessive 
osteoclastogenesis through TLR4-IFNβ signaling activation with autonomous 
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국문초록
파골세포 분화에 대한 합토글로빈의 역할
서울대학교 대학원 세포 및 발생 생물학 전공
(지도교수: 이 장 희)
진 원 종
골 대사 조절에는 골 형성 세포인 조골세포와 골 흡수 세포인
파골세포의 균형적인 활동으로 이루어 지며 골 발생과 골 재생에
주요하게 작용한다. 불균형적인 파골세포의 과도한 골 흡수는 골 밀
도를 하락시켜 골다공증, 파제트병, 자가면역관절염 등의 골 질환을
94
유도하게 된다. 골 환경에서 조골세포로부터 생성되는 시토카인인
M-CSF와 RANKL는 파골세포의 분화를 촉진하고 골 흡수능을 증
가시키게 된다. 본 연구는 조골세포에서 발현되는 합토글로빈이 어
떤 메커니즘으로 파골세포의 분화를 조절하는지 조사하였다. 마이크
로시티를 통한 정량화 분석으로 합토글로빈 유전자가 결손된 실험
동물은 파골세포가 증가되고 골 소실을 유발함을 관찰하였다. 세포
수준에서 합토글로빈의 자극은 파골세포로의 분화를 억제함을 확인
하였고, 파골세포 분화에 필요한 중요 전사인자인 c-Fos와
NFATc1의 발현이 억제되는 것을 확인하였다. 레트로바이러스를
통한 c-Fos 의 과발현은 파골세포 분화에 대한 합토글로빈의 억제
효과가 상쇄되는 것을 확인하였다. 합토글로빈으로 인한 전사인자의
발현억제에 인터페론 베타가 관여함을 확인하였고, 인터페론 수용체
의 결손은 합토글로빈의 억제효과가 사라지는 것을 관찰하였다. 이
로써 합토글로빈은 인터페론 베타를 증가시켜 파골세포 분화에 중
요하게 작용하는 c-Fos를 억제하는 메커니즘을 확인하였다. 합토
글로빈의 자극으로인한 인터페론 베타의 증가가 어떤 수용체로 통
해 일어나는지 확인해본 결과, TLR4가 관여함을 확인하였다. 파골
세포의 전구세포인 대식세포와 조골세포의 동시배양조건에서 염증
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인자중 하나인 인터류킨1 알파의 자극은 파골세포로의 분화를 유도
하게 되는데, 합토글로빈이 결손된 조골세포는 파골세포 분화를 더
욱 촉진함을 관찰하였다. 이로써 염증인자로 인해 증가되는 합토글
로빈은 과도한 파골세포로의 분화를 억제하는 기능을 갖고 있음을
확인하였다. 위 결과를 토대로 합토글로빈은 조골세포와 파골세포의
적절한 균형을 유지하기 위한 인자로 작용하며, 과도한 파골세포분
화로 인한 골 소실 억제에 관여함으로 골의 항상성을 유지함을 확
인하였다. 나아가 합토글로빈은 염증환경에서 과도한 파골세포의 골
흡수능을 억제할 수 있는 치료제로서의 가능성을 제시한다.
96
주요어 : 조골세포, 파골세포, 합토글로빈, c-Fos, 인터페론 베타,
TLR4
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